Ophthalmic Compositions and Methods of Using the Same
Ophthalmic compositions are provided that comprise or consist essentially of (a) ketotifen or a ketotifen salt, (b) a non-ionic tonicity agent, and (c) water. The concentration of ketotifen or the ketotifen salt is preferably from 0.01% to 0.05%. The non-ionic tonicity agent is preferably glycerol and the concentration of the glycerol is preferably from 4% to 7%. The compositions preferably have an osmolality of from 400 to 875 milliosmoles/Kg. The compositions may also contain an anti-redness agent. Methods of treating allergic conjunctivitis using the ophthalmic compositions and methods of treating dry eye disease using the ophthalmic compositions are also provided.
1 - 37 . (canceled)
38 . A method of treating allergic conjunctivitis, comprising administering to a subject suffering from or susceptible to allergic conjunctivitis an effective amount of an ophthalmic composition that comprises (a) ketotifen or a ketotifen salt in a concentration of from 0.01% to 0.05%; (b) a non-ionic tonicity agent in a concentration such that the composition has an osmolality of from 400 to 875 milliosmoles/Kg; (c) an anti-redness agent; and (d) water.
39 . The method of claim 38 , wherein the composition comprises ketotifen fumarate in a concentration of from 0.03% to 0.04%, glycerol in a concentration such that the composition has an osmolality of from 650 to 700 milliosmoles/Kg, and water.
40 . A method of treating allergic conjunctivitis, comprising administering to a subject suffering from or susceptible to allergic conjunctivitis an effective amount of an ophthalmic composition that comprises (a) ketotifen or a ketotifen salt in a concentration of from 0.01% to 0.05%; (b) glycerol in a concentration of from 3.5% to 7%; (c) an anti-redness agent; and (d) water.
41 . The method of claim 40 , wherein the composition comprises ketotifen fumarate in a concentration of from 0.03% to 0.04%, glycerol in a concentration of from 5.75% to 6.25%, and water.
42 . A method of treating allergic conjunctivitis, comprising administering to a subject suffering from or susceptible to allergic conjunctivitis an effective amount of an ophthalmic composition that comprises (a) ketotifen or a ketotifen salt in a concentration of from 0.01% to 0.05%; (b) glycerol in a concentration of greater than 3.5% such that the composition has an osmolality of from 400 to 875 milliosmoles/Kg; (c) an anti-redness agent; and (d) water.
43 . The method of claim 42 , wherein the composition comprises ketotifen fumarate in a concentration of from 0.03% to 0.04%, glycerol in a concentration of from 5.5% to 6.5% such that the composition has an osmolality of from 650 to 700 milliosmoles/Kg, and water.
44 . The method of claim 43 , wherein the composition comprises ketotifen fumarate in a concentration of 0.0345%, glycerol in a concentration of from 5.75% to 6.25%, benzalkonium chloride in a concentration of 0.01%, and water, and wherein the pH of the composition is from 4.4 to 5.8.
45 . A method of treating dry eye disease comprising administering to a human subject suffering from dry eye disease an effective amount of an ophthalmic composition that comprises (a) ketotifen or a ketotifen salt in a concentration of from 0.01% to 0.05%; (b) a non-ionic tonicity agent in a concentration such that the composition has an osmolality of from 400 to 875 milliosmoles/Kg; (c) an anti-redness agent; and (d) water.
46 . A method of treating dry eye disease comprising administering to a human subject suffering from dry eye disease an effective amount of an ophthalmic composition that comprises (a) ketotifen or a ketotifen salt in a concentration of from 0.01% to 0.05%; (b) glycerol in a concentration of from 3.5% to 7%; (c) an anti-redness agent; and (d) water.
47 . A method of treating dry eye disease comprising administering to a human subject suffering from dry eye disease an effective amount of an ophthalmic composition that comprises (a) ketotifen or a ketotifen salt in a concentration of from 0.01% to 0.05%; (b) glycerol in a concentration of greater than 3.5% such that the composition has an osmolality of from 400 to 875 milliosmoles/Kg; (c) an anti-redness agent; and (d) water.
48 . The method of claim 46 , wherein the ophthalmic composition comprises ketotifen fumarate in a concentration of 0.0345%, glycerol in a concentration of from 5.75% to 6.25%, benzalkonium chloride in a concentration of 0.01%, an anti-redness agent, and water.